Amgen (AMGN) Stock Forecast & Price Target

Amgen is supported by a diversified portfolio of established blockbuster therapies and newer growth drivers that reduce reliance on any single product, with Repatha showing strong momentum as July 2026 TRx rose about 32% year over year and NRx about 38%, while the broader biosimilar and specialty portfolios add additional durability. Its outlook is further strengthened by a pipeline and acquisition strategy that has expanded the franchise into oncology, rare disease, and immunology through assets such as Kyprolis, Blincyto, Imdelltra, and Tepezza, helping offset manageable loss-of-exclusivity pressure over the next few years. The fundamental thesis is also underpinned by the company’s ability to advance biologics in large addressable markets—especially cardiovascular disease and inflammation—where high visibility into continued aggressive growth from workhorse brands like Repatha and Tezspire, alongside early-life products like Uplizna and Imdelltra, supports rising sales estimates and a constructive long-term view.

Amgen is viewed negatively because, despite a broad and diversified portfolio across oncology, cardiovascular disease, bone health, inflammation, rare disease, and biosimilars, the company still faces a fundamental question around whether its Lp(a) biology will translate into actual cardiovascular risk reduction, leaving one of its mechanistically promising programs without clear causal proof. The balance sheet and valuation context also look constraining, with roughly $14B of cash against $57.3B of debt and an implied 16x 2027E EBITDA of $19,009M, which limits financial flexibility if pipeline execution disappoints or integration demands remain elevated. Although Tezspire is showing strong growth, with TRx up about 49% through July in 2026 and NRx up about 61% through July in 2026, reliance on continued aggressive volume gains, label expansion, and pending Phase III readouts adds execution risk, while the broader pipeline still includes programs that have only shown numerical, not statistical, superiority.